Canaccord cuts Intra-Cellular stock rating, raises target to $132
Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...
Atopic Dermatitis Affects Millions, And Johnson & Johnson Is Committed To Addressing The Unmet Needs Of Patients
AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...
Johnson & Johnson's SWOT analysis: stock outlook amid oncology growth and biosimilar challenges
Johnson & Johnson (NYSE:JNJ), a global healthcare giant, finds itself at a critical juncture as it navigates a complex landscape of opportunities and challenges. The company's recent performance and ...
ktiv2d
Healthbeat 4: Tips on how to navigate through winter depression
Winter depression can take a toll on your mind and body. Local health experts say depression is something you should take ...
verywellhealth2d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
WebMD3d
What to Know About the New Nasal Spray for Tough Depression
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
Renal & Urology News3d
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
Medical News Today3d
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...